دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Front Cover
Peter Rossing MD, Justus G. Garweg MD, Stefan D. Anker MD, Takeshi Osonoi PhD, Bertram Pitt MD, Sylvia E. Rosas MD, Luis Miguel Ruilope MD, Dalong Zhu MD, Meike Brinker MD, David Finis MD, Sergio Leal MD, Thomas Schmelter PhD, George Bakris MD,Â
doi : 10.1111/dom.14995
Volume 25, Issue 3
Back Cover
Yan Zhao MD, Yuchan Zheng MS, Yixin Tian MS, Qian Yu MS, Lijun Qin MS, Kai Xu MD, Biao Sun MS, Christian Benedict PhD, Baoyi Chen MD, Lijun Wei MD, Xiao Tan PhD,Â
doi : 10.1111/dom.14996
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes
Marc Evans MD, Sasha Berry MSc, Avideh Nazeri MD, Samuel JP Malkin MSc, Donna Ashley MSc, Barnaby Hunt MSc, Stephen C Bain FRCP,Â
doi : 10.1111/dom.14917
The clinical evidence base for evaluating modern type 2 diabetes interventions has expanded greatly in recent years, with numerous efficacious treatment options available (including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors).
A multicentre, randomized, double-blind, parallel, active- and placebo-controlled Phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: A study protocol
Ying Du MD, Leili Gao MD, Xinhua Xiao MD, Xin Hou MSc, Linong Ji MD,Â
doi : 10.1111/dom.14909
To report the rationale for using PB-201, a partial glucokinase activator (GKA), for a Phase 3 study (NCT05102149) assessing its efficacy and safety in a Chinese population and to describe the design of this GKA Phase 3 trial, the first to involve both an active control and a placebo control arm.
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
Philip D. Home DM, Rory J. McCrimmon MD, Julio Rosenstock MD, Matthias Blüher MD, Katrin Pegelow PhD, Lydie Melas-Melt MSc, Khier Djaballah MD, Francesco Giorgino MD, on behalf of the SoliMix trial investigators ,Â
doi : 10.1111/dom.14907
To report prespecified and post hoc analyses of the SoliMix dataset exploring the impact of baseline participant characteristics on the original SoliMix study outcomes, to enable informed treatment choices for people with different biomedical characteristics.
Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis
Fengling He MD, Wei Chen MD, Wenlong Xu MD, Dan Liu MD, Zhiwen Xiao MD, Yating Tang MD, Zhongqiu Lin MD, Yulin Liao PhD, Jianping Bin PhD, GuoJun Chen PhD, Yanmei Chen PhD,Â
doi : 10.1111/dom.14908
To assess the efficacy and safety of liraglutide to reduce visceral and ectopic fat in adults with or without type 2 diabetes mellitus (T2DM).
Nomogram model and risk score to predict 5-year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model
Yong Han MD, Haofei Hu MD, Yufei Liu MD, Zhibin Wang MD, Dehong Liu MD,Â
doi : 10.1111/dom.14910
To develop a personalized nomogram and risk score to predict the 5-year risk of diabetes among Chinese adults with prediabetes.
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results
Daria Igudesman PhD, Jamie Crandell PhD, Karen D. Corbin PhD, Dessi P. Zaharieva PhD, Ananta Addala DO MPH, Joan M. Thomas MS, Anna Casu MD, M. Sue Kirkman MD, Teeranan Pokaprakarn PhD, Michael C. Riddell PhD, Kyle Burger PhD, Richard E. Pratley MD, Michael R. Kosorok PhD, David M. Maahs MD, Elizabeth J. Mayer-Davis PhD, for the ACTION Study Group ,Â
doi : 10.1111/dom.14911
Co-management of weight and glycaemia is critical yet challenging in type 1 diabetes (T1D). We evaluated the effect of a hypocaloric low carbohydrate, hypocaloric moderate low fat, and Mediterranean diet without calorie restriction on weight and glycaemia in young adults with T1D and overweight or obesity.
Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus
Sung-Chen Liu MD, Shih-Ming Chuang MD, Chao-Hung Wang MD, Ming-Nan Chien MD, Chun-Chuan Lee MD, Wei-Che Chen MD, Ching-Hsiang Leung MD, Jiun-Lu Lin MD,Â
doi : 10.1111/dom.14912
To explore the effect of active insulin titration versus usual titration on glycaemic control in patients with type 2 diabetes mellitus uncontrolled with oral antidiabetic drugs (OADs).
Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes
Mei-zhen Wu MD, Tiew-Hwa Katherine Teng PhD, Wan-Ting Tay MAppStat, Qing-wen Ren MD, Jasper Tromp MD, Wouter Ouwerkerk PhD, Chanchal Chandramouli PhD, Jia-Yi Huang MD, Yap-Hang Chan MBBS, Kanako Teramoto MD, Si-Yeung Yu BSc, Claire Lawson PhD, Hang-Long Li BSc, Yi-Kei Tse BSc, Xin-li Li PhD, Denise Hung BSc, Hung-Fat Tse MD, Carolyn S. P. Lam PhD, Kai-Hang Yiu PhD,Â
doi : 10.1111/dom.14916
To investigate the interplay of incident chronic kidney disease (CKD) and/or heart failure (HF) and their associations with prognosis in a large, population-based cohort with type 2 diabetes (T2DM).
Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects
Minglan Yang MD, Jie Chen MM, Jiang Yue MD, Shenyun He BSc, Jingjing Fu MN, Yicheng Qi MD, Wen Liu MD, Hua Xu MM, Shengxian Li MD, Qing Lu MD, Jing Ma MD,Â
doi : 10.1111/dom.14918
To investigate the distribution of abdominal fat, particularly ectopic fat accumulation, in relation to glucose metabolism in overweight/obese patients.
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs and mortality
Sofie Persson PhD, Kristoffer Nilsson MSc, Kristina Karlsdotter PhD, Josefin Skogsberg PhD, Staffan Gustavsson BSc, Johan Jendle PhD, Katarina Steen Carlsson PhD,Â
doi : 10.1111/dom.14919
To assess hospital-based care, work absence, associated costs, and mortality in patients with type 2 diabetes with and without established cardiovascular disease (eCVD) compared to matched controls.
Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice
Loek J. M. de Heide MD, Sterre H. T. Wouda BSc, Vincent J. T. Peters PhD, Mirjam Oosterwerff-Suiker MD, Victor A. Gerdes MD, Marloes Emous MD, André P. van Beek MD,Â
doi : 10.1111/dom.14920
To evaluate medical and surgical treatment of postbariatric hypoglycaemia (PBH) in daily practice.
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Kristoffer Nilsson MSc, Emelie Andersson, Sofie Persson PhD, Kristina Karlsdotter PhD, Josefin Skogsberg PhD, Staffan Gustavsson BSc, Johan Jendle PhD, Katarina Steen Carlsson PhD,Â
doi : 10.1111/dom.14921
To perform a model-based analysis of the short- and long-term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin
Karen D. Corbin PhD, Samuel Dagogo-Jack MD, Christopher P. Cannon MD, David Z.I. Cherney MD, Francesco Cosentino MD, Robert Frederich MD, Jie Liu MD, Annpey Pong PhD, Jianxin Lin MS, Nilo B. Cater MD, Richard E. Pratley MD,Â
doi : 10.1111/dom.14923
To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study.
Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data
Thorsten Otto MSc, Joanna Diesing BS, Julia Borchert Dipl, Elke Heitmann PhD, Nanette C. Schloot MD, Jeremie Lebrec PhD, Dirk Müller-Wieland MD, Dennis Haeckl PhD,Â
doi : 10.1111/dom.14924
This study evaluates type 2 diabetes mellitus (T2DM) prevalence in Germany, focusing on patients at risk for, or with already established, cardiovascular disease (CVD), as well as their antidiabetic and cardiovascular treatments.
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry
Stephan Kress MD, Peter Bramlage MD, Reinhard W. Holl MD, Christian Dominik Möller MD, Steffen Mühldorfer MD, Jörg Reindel MD, Jochen Seufert MD, Rüdiger Landgraf MD, Ludwig Merker MD, Sebastian M. Meyhöfer MD, Thomas Danne MD, Peter Fasching MD, Peter R. Mertens MD, Christoph Wanner MD, Stefanie Lanzinger PhD,Â
doi : 10.1111/dom.14925
To validate a recently proposed risk prediction model for chronic kidney disease (CKD) in type 2 diabetes (T2D).
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
Leili Gao MD, Zhifeng Cheng MD, Benli Su MD, Xiuhai Su MB, Weihong Song MB, Yushan Guo MM, Lin Liao MD, Xiaowen Chen MM, Jiarui Li MM, Xingrong Tan MM, Fangjiang Xu MB, Shuguang Pang MD, Kun Wang MD, Jun Ye MB, Yuan Wang MD, Lili Chen MD, Jingfang Sun MM, Linong Ji MD,Â
doi : 10.1111/dom.14926
To evaluate the efficacy and safety of janagliflozin in Chinese patients with type 2 diabetes (T2D) inadequately controlled with metformin monotherapy.
Effects of intensive blood pressure lowering in patients with diabetes: A pooled analysis of the STEP and ACCORD-BP randomized trials
Ruixue Yang PhD, Jingjing Bai MS, Zhou Fang MD, Yang Wang MS, Yingqing Feng MD, Yunlan Liu MD, Hongjie Chi MD, Yue Deng PhD, Qirui Song PhD, Jun Cai MD,Â
doi : 10.1111/dom.14927
To determine whether intensive systolic blood pressure (SBP) lowering can benefit hypertensive patients with diabetes.
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
Ryosuke Ono MS, Kenichi Furihata MD, Yoshihiko Ichikawa MD, Yoshiomi Nakazuru PhD, Arthur Bergman PhD, Donal N. Gorman PhD, Aditi R. Saxena MD,Â
doi : 10.1111/dom.14928
This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), which is a novel, oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese participants with type 2 diabetes mellitus (T2DM).
Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial
Kitti Thammakosol MD, Chutintorn Sriphrapradang MD,Â
doi : 10.1111/dom.14929
To determine the effectiveness and safety of early combination of insulin glargine with intravenous (IV) insulin infusion compared with IV insulin infusion alone in the management of diabetic ketoacidosis (DKA).
Objective sleep characteristics and continuous glucose monitoring profiles of type 2 diabetes patients in real-life settings
Yan Zhao MD, Yuchan Zheng MS, Yixin Tian MS, Qian Yu MS, Lijun Qin MS, Kai Xu MD, Biao Sun MS, Christian Benedict PhD, Baoyi Chen MD, Lijun Wei MD, Xiao Tan PhD,Â
doi : 10.1111/dom.14930
To investigate the association between objective sleep parameters and glycaemic variability determined by continous glucose monitoring (CGM) among patients with type 2 diabetes, given the significant role of sleep in glycaemic control.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
Susanna Bianzano MD, Matias Nordaby MD, Leona Plum-Mörschel MD, Barbara Peil PhD, Tim Heise MD,Â
doi : 10.1111/dom.14932
To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity.
Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
Niels H. Brandt-Jacobsen MD, Mikkel Jürgens MD, Philip Hasbak MD, Peter Gæde MD, Peter Rossing MD, Jon J. Rasmussen MD, Camillla Fuchs Andersen MD, Julie L. Forman PhD, Jens Faber MD, Silvio E. Inzucchi MD, Finn Gustafsson MD, Morten Schou MD, Caroline Kistorp MD,Â
doi : 10.1111/dom.14933
Ectopic accumulation of cardiac adipose tissue volume (CAT) has been associated with cardiac remodelling and cardiac dysfunction in type 2 diabetes and may be a future therapeutic target. In this substudy from the SIMPLE-trial, we investigated short-term empagliflozin therapy's effects on CAT in patients with type 2 diabetes.
Peripherally restricted oxytocin is sufficient to reduce food intake and motivation, while CNS entry is required for locomotor and taste avoidance effects
Mohammed Asker MSc, Jean-Philippe Krieger PhD, Amber Liles MSc, Ian C. Tinsley PhD, Tito Borner PhD, Ivana Maric MSc, Sarah Doebley BSc, C. Daniel Furst MSc, Stina Börchers MSc, Francesco Longo PhD, Yashaswini R. Bhat BS, Bart C. De Jonghe PhD, Matthew R. Hayes PhD, Robert P. Doyle PhD, Karolina P. Skibicka PhD,Â
doi : 10.1111/dom.14937
Oxytocin (OT) has a well-established role in reproductive behaviours; however, it recently emerged as an important regulator of energy homeostasis. In addition to central nervous system (CNS), OT is found in the plasma and OT receptors (OT-R) are found in peripheral tissues relevant to energy balance regulation. Here, we aim to determine whether peripheral OT-R activation is sufficient to alter energy intake and expenditure.
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy
Olivia M. McCarthy PhD, Kasper Birch Kristensen MD, Merete Bechmann Christensen MD, Signe Schmidt MD, Ajenthen G. Ranjan MD, Chloe Nicholas MSc, Stephen C. Bain MD, Kirsten Nørgaard MD, Richard Bracken PhD,Â
doi : 10.1111/dom.14938
To profile acute glycaemic dynamics during graded exercise testing (GXT) and explore the influence of glycaemic indicators on the physiological responses to GXT in adults with type 1 diabetes using insulin pump therapy.
Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes
Hood Thabit PhD, Charlotte Boughton PhD, Womba Mubita RN, Jose Rubio RN, Julia K. Mader MD, Parth Narendran PhD, Mark Evans MD, Lalantha Leelarathna, Malgorzata E Wilinska PhD, Catherine Fullwood PhD, Alice M Gregory PhD, Roman Hovorka PhD, Martin K Rutter MD,Â
doi : 10.1111/dom.14914
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)
Peter Rossing MD, Justus G. Garweg MD, Stefan D. Anker MD, Takeshi Osonoi PhD, Bertram Pitt MD, Sylvia E. Rosas MD, Luis Miguel Ruilope MD, Dalong Zhu MD, Meike Brinker MD, David Finis MD, Sergio Leal MD, Thomas Schmelter PhD, George Bakris MD,Â
doi : 10.1111/dom.14915
